REG - Immupharma PLC - Notice of AGM & Annual Report & Accounts

ImmuPharmaAnnouncement

05/06/2024 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240605:nRSE2666Ra&default-theme=true

RNS Number : 2666R  Immupharma PLC  05 June 2024

 

 

 

 

RNS:
RELEASE
5 June 2024

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Notice of AGM & Annual Report & Accounts

 

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, is pleased to confirm that the Company's Annual General Meeting
("AGM") will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices
of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG.

 

The Notice of AGM setting out details of the resolutions, together with the
Company's Annual Report and Accounts for the year ended 31 December 2023, has
been posted to those shareholders requesting a postal copy; and for other
shareholders, these documents will shortly be available to view and download
on the Company's website: www.immupharma.co.uk (http://www.immupharma.co.uk) .

 

Ends

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk)                + 44 (0) 207 206 2650

 Tim McCarthy, Chairman and Chief Executive Officer
 Lisa Baderoon, Head of Investor Relations            + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)              +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)             +44 (0) 203 815 8880

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                            +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140 is a first-in class autophagy
immunomodulator for the treatment of Lupus and CIDP and preclinical analysis
suggests P140 may have therapeutic benefit in many other autoimmune diseases
that are caused by the same dysfunction in the immune system.

 

For additional information about ImmuPharma please visit: www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSLELFBZQLEBBK